© 2024 HSP News Service, L.L.C.
The recent approval of mirvetuximab soravtansine-gynx is a testament to the emerging benefit of antibody-drug conjugates in recurrent ovarian cancer. Other agents of this class are now eliciting excitement as they demonstrate high response rates in a population with unmet clinical needs, according...
A blood-based, machine learning assay that combines cell-free DNA (cfDNA) fragmentomes and protein biomarkers was able to differentiate patients with ovarian cancer from healthy controls at a high specificity of more than 99%, according to study results by Medina et al.1 It noninvasively recognized ...
The session’s invited discussant at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer was Gini F. Fleming, MD, Professor of Medicine, and Medical Director of Gynecologic Oncology at the University of Chicago. She was elated with the findings of several studies showing...
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced or recurrent endometrial cancer not only reduced the risk of disease progression but improved overall survival, particularly for the mismatch repair–deficient/microsatellite instability–high...
Researchers have found that spatial tissue analysis may help predict early posttreatment relapse and illuminate new potential therapies in patients with high-grade serous ovarian carcinoma, according to a recent study published by Xu et al in Science Advances. Background Many patients with...
As reported in The Lancet Oncology by Ana Oaknin, MD, of the Medical Oncology Service at Vall d´Hebron Institute of Oncology, Vall d´Hebron Barcelona Hospital, and colleagues, the phase I/II CheckMate 358 trial showed that both nivolumab monotherapy and nivolumab/ipilimumab regimens were active...
In a phase II trial (NRG Oncology/GOG Study 279) reported in the Journal of Clinical Oncology, Horowitz et al found that concurrent cisplatin, gemcitabine, and intensity-modulated radiation therapy (IMRT) produced a high rate of complete pathologic response in patients with locally advanced vulvar...
The combination of immunotherapy, targeted therapy, and chemotherapy could be the new standard first-line treatment of patients with high-grade, advanced ovarian cancer with BRCA wild-type, homologous recombination deficiency (HRD)-positive tumors, according to data presented during the Society of...
Investigators have uncovered genetic variants that may predispose certain female patients to prevalent or persistent human papillomavirus (HPV) infections and increase their risk of developing cervical cancer, according to a recent study published by Adebamowo et al in the European Journal of Human ...
Ovarian cancer is the eighth most-common cancer among women globally, and the eighth most-common cause of death from cancer worldwide. In the United States alone, in 2023, there were nearly 20,000 new cases of the cancer, and about 13,270 deaths from the disease. Ovarian cancer is largely...
Ana Oaknin, MD, PhD, of Spain’s Vall d’Hebron University Hospital, discusses phase III findings from the BEATcc trial, showing that adding atezolizumab to a standard bevacizumab-plus-platinum regimen for patients with metastatic, persistent, or recurrent cervical cancer significantly improves survival outcomes and may be considered a new first-line treatment option.
The combination of the antibody-drug conjugate mirvetuximab soravtansine-gynx and the immune checkpoint inhibitor pembrolizumab showed notable activity in patients with recurrent or persistent microsatellite-stable endometrial cancer, according to new findings presented by Porter et al at the...
As reported in The Lancet Oncology by Domenica Lorusso, MD, PhD, and colleagues, the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial has shown that the addition of pembrolizumab to chemoradiotherapy improved progression-free survival in patients with newly diagnosed, high-risk, locally advanced...
On January 12, 2024, pembrolizumab (Keytruda) was approved for use with chemoradiotherapy for treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 stage III–IVA cervical cancer.1 Supporting Efficacy Data Approval was based on findings in the double-blind...
Matthew A. Powell, MD, of the Washington University School of Medicine, discusses phase III findings from the RUBY trial, which shows dostarlimab-gxly plus chemotherapy improves overall survival in patients with primary advanced or recurrent endometrial cancer, regardless of mismatch repair status. According to Dr. Powell, this regimen could become a new standard of care.
Anne Knisely, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings showing that patients with ovarian cancer who undergo second-look laparoscopy and are found to have measurable residual disease (MRD) as well as circulating tumor DNA (ctDNA) after front-line therapy have a particularly poor prognosis. These data suggest treatments should be individualized by stratifying risk, and front-line clinical trials of ovarian cancer should use MRD as a surrogate endpoint.
Statistically significant and clinically meaningful overall survival results from Part 1 and progression-free survival results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial in adult patients with primary advanced or recurrent endometrial cancer were presented in a late-breaking...
On March 22, the U.S. Food and Drug Administration (FDA) approved mirvetuximab soravtansine-gynx (Elahere) for adult patients with folate receptor–alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic ...
Mary McCormack, PhD, MBBS, of University College London Hospitals, NHS Foundation Trust, discusses the global health issue of cervical cancer and a way forward. Phase III findings from the GCIG INTERLACE trial showed that induction chemotherapy with weekly paclitaxel and carboplatin before chemoradiation not only improved survival outcomes, it is feasible across diverse health-care settings and may be considered a new standard in locally advanced cervical cancer.
The combination of avelumab and axitinib may be effective in patients with mismatch repair–proficient recurrent or persistent endometrial cancer, according to new findings presented by Lee et al at the Society of Gynecologic Oncology’s (SGO) 2024 Annual Meeting on Women’s Cancer. Background...
Mansoor R. Mirza, MD, of Copenhagen University Hospital, discusses follow-up results from the RUBY trial, showing that, for patients with primary advanced or recurrent endometrial cancer, dostarlimab-gxly plus chemotherapy followed by dostarlimab-gxly plus niraparib improved progression-free survival in the overall and subgroup populations. Given the potential role for PARP inhibitor maintenance, the study is ongoing to obtain overall survival data.
Brian M. Slomovitz, MD, of Mount Sinai Medical Center, Miami Beach, discusses additional phase III data from the innovaTV 301 trial, which showed that in patients with previously treated recurrent or metastatic cervical cancer, tisotumab vedotin-tftv was more efficacious than chemotherapy as second- or third-line treatment. According to Dr. Slomovitz, this agent may be considered a potential new standard of care in this population.
Latest analysis of the results from the phase III DUO-E trial showed durvalumab plus platinum-based chemotherapy followed by durvalumab plus olaparib demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair–proficient (pMMR) advanced or ...
The artificial intelligence (AI)-based chatbot ChatGPT version 3.4 may correctly answer a majority of the common genetic counseling questions related to gynecologic oncology, according to new findings presented by Patel et al at the Society of Gynecologic Oncology’s (SGO) 2024 Annual Meeting on...
Female patients with ovarian germ cell tumors may have worse prognoses compared with male patients with testicular germ cell tumors, according to a recent study published by Sköld et al in the Journal of Internal Medicine. Background Both ovarian and testicular germ cell tumors predominantly...
Investigators have uncovered that despite low adoption rates of the 2020 American Cancer Society (ACS) cervical cancer screening guidelines among physicians, a majority of them expressed willingness to utilize the recommendations under certain circumstances, according to a recent study published by ...
As reported by Marie Plante, MD, and colleagues in The New England Journal of Medicine, the phase III CX.5 SHAPE trial has shown noninferiority of simple vs radical hysterectomy in terms of pelvic recurrence in women with low-risk cervical cancer. Simple hysterectomy was associated with a reduced...
The established dual HER2 blockade of pertuzumab and trastuzumab may be an effective treatment for patients with several types of HER2-amplified cancers, according to a study published by Connolly et al in Clinical Cancer Research. Background HER2 receptors control how cells grow and divide. The...
As reported in the Journal of Clinical Oncology by Domenica Lorusso, MD, PhD, and colleagues, the Italian phase III MITO-23 trial showed no overall survival benefit with trabectedin vs chemotherapy in women with recurrent ovarian cancer with a BRCA mutation or BRCAness phenotype. Study Details In ...
The incidence and mortality of cervical cancer may be rising in patients residing in low-income areas of the United States, according to a recent study published by Amboree et al in the International Journal of Cancer. Study Methods and Results In the recent study, investigators used the...
The final survival analysis of the Dutch-Belgian phase III OVHIPEC-1 trial showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery was associated with maintained progression-free and overall survival benefits at 10 years in women with advanced ...
As reported in the Journal of Clinical Oncology by Han et al, the 21-year update of the Normal Risk Ovarian Screening Study (NROSS) has shown that the NROSS screening strategy remains effective for the detection of ovarian cancer and detection at early disease stages. Study Details The NROSS...
On January 12, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with chemoradiotherapy for patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 stage III–IVA cervical cancer. KEYNOTE-A18 Efficacy was evaluated in KEYNOTE-A18...
In the Chinese phase II NACI trial reported in The Lancet Oncology, Li et al found that neoadjuvant chemotherapy plus camrelizumab produced antitumor activity and had a manageable adverse event profile in patients with locally advanced cervical cancer. Study Details A total of 85 patients were...
The final survival analysis of the Dutch-Belgian phase III OVHIPEC-1 trial showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery was associated with maintained progression-free and overall survival benefits at 10 years in women with advanced ...
Next-generation sequencing may help better identify patients with cancer and mismatch repair deficiency who may benefit from immunotherapy, according to a recent study published by Farhat et al in Cancer Cell. The new findings indicated that treating more patients with immunotherapy may require...
As reported in The Lancet by Ana Oaknin, MD, and colleagues, the phase III BEATcc trial has shown that the addition of atezolizumab to bevacizumab and chemotherapy improved progression-free and overall survival in women with metastatic, persistent, or recurrent cervical cancer. Study Details The...
Investigators have found that implementing the updated World Health Organization (WHO) screening guidelines may effectively reduce the cervical cancer mortality rate in patients residing in low- and middle-income countries, according to two recent studies published by Simms et al and Hall et al in...
As reported in The New England Journal of Medicine by Kathleen N. Moore, MD, and colleagues, the phase III MIRASOL trial has shown improved progression-free and overall survival with mirvetuximab soravtansine-gynx vs chemotherapy in previously treated patients with folate receptor–alpha...
In a study reported in the Journal of Clinical Oncology, Han et al found that persistent human papillomavirus (HPV) circulating tumor DNA (ctDNA) after chemoradiation was associated with poorer outcomes in patients with cervical cancer. Patients at high risk of poorer outcomes could also be...
Invited discussant Krishnansu Tewari, MD, Associate Professor in the Division of Gynecologic Oncology at the University of California, Irvine, said two new approaches for locally advanced cervical cancer, as described at the European Society for Medical Oncology (ESMO) Congress 2023, represent...
In patients with newly diagnosed, locally advanced cervical cancer, induction chemotherapy prior to chemoradiation therapy led to a 35% reduction in the risk for disease recurrence or death (hazard ratio [HR] = 0.65; P = .013) and a 39% reduction in the survival hazard (HR = 0.61; P = .04),...
Based on the results of the phase III BEATcc trial, there is no longer doubt that immune checkpoint inhibitors have transformed the treatment landscape in cervical cancer—and there is no place for “skeptics” of this approach, according to Bradley J. Monk, MD, FACS, FACOG, Director and Principal...
In patients with recurrent or metastatic cervical cancer, the addition of the PD-L1–inhibiting monoclonal antibody atezolizumab to first-line chemotherapy plus the angiogenesis inhibitor bevacizumab significantly improved all efficacy outcomes and yielded a median overall survival that exceeded 2.5 ...
As reported in The Lancet Oncology by Bradley J. Monk, MD, and colleagues, the phase III CALLA trial showed no significant improvement in progression-free survival with the addition of durvalumab to chemoradiotherapy in previously untreated patients with locally advanced cervical cancer. Study...
In a UK single-institution study (EPI-SURE) reported in The Lancet Oncology, Evans et al found that the novel WID-qEC DNA methylation test outperformed ultrasonography in detecting uterine cancer in women with abnormal uterine bleeding. Study Details The prospective observational study invited...
In a Dutch retrospective cohort study reported in The Lancet Oncology, Schuurman et al identified follow-up strategies based on cytology and human papillomavirus (HPV) testing after fertility-sparing surgery for early-stage cervical cancer. Study Details The nationwide population-based study used...
In the global randomized open-label phase III innovaTV 301/ENGOT-cx12/GOG-3057 trial, treatment with the antibody-drug conjugate tisotumab vedotin-tftv resulted in a statistically significant 30% reduction in the risk of death in patients previously treated for recurrent or metastatic cervical...
In the phase III DUO-E trial, a first-line treatment regimen that includes chemotherapy plus the checkpoint inhibitor durvalumab followed by maintenance durvalumab, with or without the PARP inhibitor olaparib, significantly improved progression-free survival in patients with advanced or recurrent...
In a phase III trial (OVAL Study/GOG 3018) reported in the Journal of Clinical Oncology, Arend et al found that the addition of ofranergene obadenovec to paclitaxel did not improve survival outcomes in patients with platinum-resistant ovarian cancer. Ofranergene obadenovec is a gene-based targeted...